Evidence map›Paper›PMID 42320680›Full record

ArticleVirus research2026

Functional SLC29A3/ENT3 drives autophagic clearance of intracellular viral particles.

Arnav Joshi, Ross C Larue, Rajgopal Govindarajan

Abstract read
In one paragraph

Article in Virus research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Arnav JoshiDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA.
Ross C LarueDepartment of Cancer Biology and Genetics, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Rajgopal GovindarajanDivision of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, 43210, USA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA. Electronic address: govindarajan.21@osu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The persistence of latent HIV-1 reservoirs poses a major risk for rebound viremia, necessitating strategies that enhance the clearance of intracellular viral components. Autophagy is a critical homeostatic mechanism for clearance of damaged organelle and misfolded proteins, yet its role in HIV-1 infection is complex, as the virus often evolves mechanisms to evade autophagic degradation. In this study, we identify the lysosomal transporter SLC29A3/ENT3 as a key regulator of viral clearance. Using SLC29A3-knockdown (KD) and overexpressing (OE) HEK293-T cell models, we demonstrate that the loss of SLC29A3 significantly increases susceptibility to infection by both HIV enveloped (Clade B and C) and VSV-G enveloped HIV-1 viral particles. SLC29A3-deficient cells exhibited higher rates of host genome integration and prolonged retention of the viral capsid protein p24. Immunofluorescence microscopy revealed that the absence of SLC29A3 leads to the persistent accumulation of viral cores within endolysosomes. Conversely, SLC29A3 replenishment expedited viral clearance; a process confirmed to be autophagy-dependent through pharmacological modulation with rapamycin and chloroquine. Our findings suggest that augmenting SLC29A3 activity may provide a novel therapeutic avenue for curbing viral load by enhancing virophagy.

Indexed as

AutophagyHIV-1HIV InfectionsNucleoside Transport ProteinsVirionHEK293 CellsHumansLysosomesNucleoside Transport ProteinsSLC29A3 protein, humanEndolysosomesEquilibrative nuceloside transporterHIV-1SLC29A3Viral clearanceVirophagy

Identifiers

PMID42320680
PMCPMC13315966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.